T. Rowe Price Associates’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $391M | Buy |
5,589,560
+4,850,982
| +657% | +$251M | 0.04% | 328 |
|
|
2026
Q1 | $37.5M | Buy |
738,578
+244,565
| +50% | +$11.4M | ﹤0.01% | 859 |
|
|
2025
Q4 | $14.6M | Buy |
494,013
+11,148
| +2% | +$303K | ﹤0.01% | 1143 |
|
|
2025
Q3 | $12.5M | Sell |
482,865
-141,294
| -23% | -$3.94M | ﹤0.01% | 1172 |
|
|
2025
Q2 | $17.2M | Sell |
624,159
-18,789
| -3% | -$495K | ﹤0.01% | 989 |
|
|
2025
Q1 | $18.2M | Sell |
642,948
-430,107
| -40% | -$15.3M | ﹤0.01% | 981 |
|
|
2024
Q4 | $44.6M | Sell |
1,073,055
-386,924
| -27% | -$18.5M | 0.01% | 790 |
|
|
2024
Q3 | $97.6M | Sell |
1,459,979
-139,749
| -9% | -$12.8M | 0.01% | 569 |
|
|
2024
Q2 | $190M | Buy |
1,599,728
+580,531
| +57% | +$73.5M | 0.02% | 426 |
|
|
2024
Q1 | $109M | Sell |
1,019,197
-88,298
| -8% | -$8.9M | 0.01% | 530 |
|
|
2023
Q4 | $110M | Sell |
1,107,495
-387,543
| -26% | -$32.6M | 0.01% | 525 |
|
|
2023
Q3 | $154M | Buy |
1,495,038
+293,604
| +24% | +$32.8M | 0.02% | 439 |
|
|
2023
Q2 | $146M | Sell |
1,201,434
-411,017
| -25% | -$54.8M | 0.02% | 450 |
|
|
2023
Q1 | $248M | Sell |
1,612,451
-1,116,552
| -41% | -$184M | 0.04% | 344 |
|
|
2022
Q4 | $490M | Sell |
2,729,003
-3,714,406
| -58% | -$607M | 0.08% | 233 |
|
|
2022
Q3 | $762M | Buy |
6,443,409
+3,051,035
| +90% | +$463M | 0.12% | 163 |
|
|
2022
Q2 | $485M | Buy |
3,392,374
+973,933
| +40% | +$139M | 0.06% | 296 |
|
|
2022
Q1 | $417M | Sell |
2,418,441
-13,367
| -0.5% | -$2.25M | 0.04% | 363 |
|
|
2021
Q4 | $618M | Sell |
2,431,808
-6,282
| -0.3% | -$1.84M | 0.06% | 313 |
|
|
2021
Q3 | $938M | Buy |
2,438,090
+215,515
| +10% | +$79.5M | 0.09% | 233 |
|
|
2021
Q2 | $522M | Sell |
2,222,575
-115,320
| -5% | -$20.6M | 0.05% | 326 |
|
|
2021
Q1 | $306M | Buy |
2,337,895
+993,175
| +74% | +$144M | 0.03% | 438 |
|
|
2020
Q4 | $140M | Buy |
1,344,720
+356,183
| +36% | +$36M | 0.01% | 613 |
|
|
2020
Q3 | $69.9M | Sell |
988,537
-28,323
| -3% | -$1.97M | 0.01% | 762 |
|
|
2020
Q2 | $65.3M | Buy |
1,016,860
+491,217
| +93% | +$26.9M | 0.01% | 762 |
|
|
2020
Q1 | $15.7M | Sell |
525,643
-603,854
| -53% | -$13.9M | ﹤0.01% | 1140 |
|
|
2019
Q4 | $22.1M | Buy |
1,129,497
+334,486
| +42% | +$5.93M | ﹤0.01% | 1149 |
|
|
2019
Q3 | $12.7M | Sell |
795,011
-40,416
| -5% | -$597K | ﹤0.01% | 1253 |
|
|
2019
Q2 | $12.2M | Buy |
835,427
+15,652
| +2% | +$336K | ﹤0.01% | 1283 |
|
|
2019
Q1 | $16M | Buy |
819,775
+6,333
| +0.8% | +$118K | ﹤0.01% | 1239 |
|
|
2018
Q4 | $11.9M | Buy |
+813,442
| New | +$13.4M | ﹤0.01% | 1283 |
|
Other funds holding MRNA
TP
T. Rowe Price Associates's MRNA Position: Q2 2026 in Review
T. Rowe Price Associates increased its Moderna (MRNA) stake by 657% in Q2 2026, buying an estimated $251M and bringing the position to 5,589,560 shares worth $391M. The position accounts for 0.04% of the portfolio, ranked #328.
T. Rowe Price Associates first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $938M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- T. Rowe Price Associates held 5,589,560 shares of Moderna worth $391M as of Q2 2026.
- T. Rowe Price Associates bought 4,850,982 Moderna shares in Q2 2026, an estimated $251M.
- Moderna made up 0.04% of T. Rowe Price Associates's portfolio in Q2 2026, its #328 holding.
- T. Rowe Price Associates first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- T. Rowe Price Associates's Moderna position peaked at $938M in Q3 2021.
- 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.